Background: In controlled clinical studies, mepolizumab has been shown to reduce
exacerbation rates and the use of oral corticosteroids as well as improve asthma control and …

Rationale Results from clinical trials in patients with severe eosinophilic asthma have
demonstrated that mepolizumab is well tolerated and is associated with improved asthma …

Objective To evaluate the real-world impact of mepolizumab on the incidence of asthma
exacerbations, oral corticosteroid (OCS) use and asthma exacerbation-related costs in …

Background Patients with severe asthma frequently have associated comorbidities, which
can compound existing symptoms, complicating asthma management. Objective To …

Objective The efficacy and safety of mepolizumab in patients with severe eosinophilic
asthma in randomized controlled trials is well established. Following approval of …

Background: Asthma has a high healthcare burden globally, with up to 10% of the asthma
population suffering from severe disease. Biologic agents are a newer class of asthma …

Introduction Efficacy of mepolizumab, an anti-interleukin-5 monoclonal antibody, was
demonstrated in randomised controlled trials; data on its real-world impact in routine clinical …

Purpose Patients with life-threatening asthma typically experience recurrent exacerbations,
are dependent on oral corticosteroids (OCSs), and have considerable asthma-related health …

To the Editor, Patients with severe eosinophilic asthma experience frequent exacerbations
and may require oral corticosteroids (OCS) to maintain asthma control. 1 In randomized …

Objective To investigate the changes in asthma exacerbation, as well as in oral
corticosteroid (OCS) use, exacerbation-related healthcare resource utilization (HRU), and …